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Abstract 
Background: Sinus node dysfunction, atrioventricular (AV) block and atrial fibrillation (AF) 
are   associated   with   advanced   age.   Required   therapy   commonly   includes   pacemaker 
implantation. 
Methods: We report the course of therapy for an 87-year-old with symptomatic sinus node 
dysfunction   and   paroxysmal   atrial   fibrillation   who   was   intolerant   of   drug   therapy. 
Results: The patient  received a pacemaker for treatment of sick sinus syndrome. She continued 
to have symptomatic episodes of   AF and was intolerant of pharmacologic therapy despite 
adequate rate support provided by the pacemaker.   The AF suppression algorithm in the 
pacemaker was enabled, resulting in the elimination all AF episodes effectively eliminating the 
need for antiarrhythmic medication.   If this continues to stabilize her atrium, withdrawal of 
anticoagulation therapy is anticipated.                                                                           . 
Conclusions:  The clinical presentation of sinus node dysfunction and related conduction 
abnormalities is common in the elderly.  Pharmacologic management is often a challenge in the 
presence of the advanced age and concomitant disease processes. In individuals who have 
paroxysmal atrial fibrillation or are likely to develop this and who need a pacemaker for 
standard indications, the availability of an AF Suppression™   algorithm may facilitate their 
management without needed to use medications or being able to utilize lower doses of those 
medications.  
Clinical   History                                                                      . 
The patient is a frail 87-year-old woman with symptomatic sinus node dysfunction and 
documented paroxysmal atrial fibrillation (PAF).   She presented with PAF and presyncopal 
spells.   The presyncopal episodes coincided with episodes of sinus arrest   occurring upon 
spontaneous termination of AF. Various antiarrhythmic agents (AA) were utilized including 
digoxin 0.125 mg/d with serum digoxin level of 1.0 ng/ml, atenolol starting at 25 mg QD, 
titrating up to 50 mg BID and sotalol 80 MG BID.  All of these AA were either ineffective, 
exacerbated her bradyarrhythmia or caused intolerable side effects.  She was also placed on 
coumadin 2.5 mg alternating with 5.0 mg due to the frequent episodes of AF, with a target INR 
of 2-3.                                                                                                                           . 
A pacemaker (St. Jude Medical Integrity™ µ DR) was implanted (October 21, 2001) to provide 
dual-chamber pacing (DDD mode) to manage her symptomatic bradycardic episodes and allow 
for the safe administration of pharmacologic therapy.   The automatic mode switch function 
 (AMS) was enabled to prevent tracking of the high atrial rate by the pacemaker. It also served 
as a diagnostic marker for recurrent and possibly clinically asymptomatic episodes of PAF. This 
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 3(2): 88-90 (2003)Paul A. Levine, Robin Wachsner, Adel El-Bialy, “Pacing for the Suppression                   89 
of Paroxysmal Atrial Fibrillation in an 87-year-old Patient”
function allows internal pacemaker diagnostic records to detail   pacing and AMS events, 
enabling their quantification at patient follow-up.                                                                 . 
At five weeks, the pacing system was functioning appropriately, but the patient complained of 
fatigue.  It was rationalized that the fatigue  might be an inherent effect of  her medications. At 
this time, all medications except atenolol were discontinued and the atenolol was reduced to 25 
mg QD, to facilitate control of the ventricular response during AF.  Coumadin was continued.     
At her follow-up visit 4 months post-implant, the patient reported a marked decrease in the 
frequency, but not total elimination of her palpitations.  There was total elimination of her near 
syncopal spells. Standard DDD pacing appeared to have been effective in treating her 
presyncopal symptoms but at standard settings, episodes of paroxysmal atrial fibrillation 
continued.  The AMS event log recorded 43 episodes, most being triggered by atrial rates > 300 
bpm and consistent with AF.  Although the cumulative episodes of atrial fibrillation accounted 
for < 1% of the rhythm activity since her last evaluation, she continued to complain of the 
palpitations.   As she was intolerant of most medications, the AF Suppression™ algorithm 
integral to her implanted pacing system was enabled and a follow-up visit was scheduled in 
three months. On her return, she reported feeling well with resolution of both palpitations 
fatigue.  The AMS event log data showed no AMS episodes.  It was opted to withdraw the low 
dose of atenolol at this time but continue the coumadin.  Future plans include a follow up in six 
months and if AF remains suppressed, to discontinue coumadin anticoagulation.  
Discussion 
The AF Suppression™ algorithm is a newly approved algorithm designed to provide a high 
percentage of atrial overdrive pacing which usurps the control of the atrial rate, either from the 
sinus node or an ectopic foci.    The objective is reduced temporal dispersion of the atrial 
refractory period combined with overdrive suppression of ectopic beats, a common trigger for 
atrial tachyarrhythmias.   AMS remains functional with the AF Suppression™ algorithm on, 
thus if AF occurs, AMS is activated facilitating management as this provides information as to 
the frequency and duration of each AMS episode.  Based on the detected atrial rate, one can 
infer the mechanism of the atrial arrhythmia with the faster episodes being atrial fibrillation.  
Sinus node dysfunction, AV block and AF  progressively increase in frequency with advancing 
age.1   Standard treatment for symptomatic bradyarrhythmias is pacing while rapid heart rhythms 
are commonly treated pharmacologically.  2,3    However, pharmacologic therapy is often a 
challenge   in   the   very   elderly   (   >   85)   due   to   alterations   in   pharmacokinetics   and 
pharmacodynamics.  Management of these patients becomes a complex task, particularly when 
the number of medications prescribed increases and one has to be concerned with adverse drug 
interactions and side effects.4  Device therapy is the standard approach to the management of a 
symptomatic bradycardia.   The majority of pacemaker patients are elderly, with more than 85% 
of pacemaker recipients being at least 64 years old.5 Thus, as the technology and features of 
pacemakers improve, it is important for the clinician to understand how these technological 
advances can optimize patient care.
AF is specific arrhythmia associated with age, either by itself or in conjunction with other 
conduction abnormalities.  The prevalence of AF doubles for each decade of life after age 60.6 
Although not lethal, patients with AF have twice the risk for death, and if not on anticoagulant 
therapy, a five-fold risk for stroke.  This risk escalates in patients 75 and older.7   Quality of life 
is also compromised as a consequence of the loss of atrial transport and the irregular and often 
rapid ventricular rates.  The initial treatment of AF is pharmacologic designed to either restore 
sinus rhythm or to control the ventricular response to this rhythm.  In those individuals who have 
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the bradycardia-tachycardia syndrome, dizziness and/or syncope are commonly associated with 
the protracted asystolic pauses following spontaneous termination of a paroxysmal atrial 
fibrillation   episode.   Pharmacologic   therapy   may   exacerbate   these   symptoms   by   further 
lengthening the sinus node recovery time following spontaneous termination of an episode as 
well as exacerbating the underlying bradycardia when in sinus rhythm.  A common treatment for 
PAF   associated   with   bradycardia-tachycardia   syndrome   is   implantation   of   a   permanent 
pacemaker in combination with drugs, as was done in this case.8  Although drug therapy is the 
initial therapy, the majority of cardiovascular agents, can have deleterious effects in the geriatric 
population requiring careful attention to management.9  
           The decision at the time of implantation was to select a device with a commercially 
available overdrive suppression algorithm although there was no way to determine whether or 
not it would be successful in this patient prior to its implantation.    The addition of the 
commercially approved AF Suppression™ algorithm proved to be a valuable adjunct to this 
patient's management allowing us to discontinue a multiplicity of medications. We cannot 
determine whether it was stabilization of her atrial rhythm or elimination of her polypharmacy 
that accounted for her clinical improvement but both were made possible by technologic 
advances in the form of the AF Suppression algorithm. While the algorithm may not be 100% 
effective in all patients, any reduction in the number of AF episodes is beneficial. In this case, 
standard pacing resulted in a marked improvement for the patient, but episodes of symptomatic 
and asymptomatic PAF continued. The ability to then enable the AF Suppression™ algorithm 
provided additional benefit, further improving this patient’s quality of life as well as allowing 
discontinuation of her current antiarrhythmic medications. Although this is an isolated case, the 
use of a pacemaker containing the AF Suppression™ algorithm should be considered in all 
patients undergoing device implant for a symptomatic bradycardia, particularly when there is a 
prior history of atrial fibrillation or they are at increased risk of atrial fibrillation which is more 
likely when the indication for pacing is sinus node dysfunction.   
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